

Zeposia (ozanimod)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Zeposia (ozanimod)	1
Summary	2
Definitions	2
Clinical Indications	4
Medical Necessity Criteria for Clinical Review	4
General Medical Necessity Criteria	4
Medical Necessity Criteria for Initial Clinical Review	4
Initial Indication-Specific Criteria	4
Multiple Sclerosis - Adults	4
Ulcerative Colitis	5
Medical Necessity Criteria for Subsequent Clinical Review	5
Subsequent Indication-Specific Criteria	5
Multiple Sclerosis - Adults	5
Ulcerative Colitis	6
Experimental or Investigational / Not Medically Necessary	7
References	7
Clinical Guideline Revision / History Information	9

Summary

Zeposia (ozanimod) is a sphingosine 1-phosphate (S1P) receptor modulator approved for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease; and, moderately to severely active ulcerative colitis (UC) in adults. It works by reducing the migration of lymphocytes to sites of inflammation, potentially reducing disease activity in both conditions. In those prescribed Zeposia (ozanimod), anti-neoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies should co-administered with caution due to the additive immunosuppressive effects.

1. Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system. It typically presents in young adults (generally diagnosed before 50 years of age) with symptoms such as vision problems, muscle weakness, numbness, and difficulty with balance and coordination. The most common form is relapsing-remitting MS (occurring in about 85% of patients), characterized by acute attacks followed by periods of remission. Treatment goals include reducing relapses, slowing disability progression, and managing symptoms. Disease-modifying therapies (DMTs) are the primary treatment approach and include injectable medications (e.g., interferons, glatiramer acetate), oral medications (e.g., dimethyl fumarate, fingolimod, teriflunomide, etc.), and infusion therapies (e.g., natalizumab, ocrelizumab).
2. Ulcerative Colitis (UC) is a chronic inflammatory bowel disease that affects the colon and rectum. It is characterized by periods of active disease and remission, with symptoms including bloody diarrhea, abdominal pain, and urgency. For UC, treatment goals include inducing and maintaining remission, with options ranging from anti-inflammatory drugs to biologics.

Definitions

"Clinically isolated syndrome" refers to a first episode of neurologic symptoms lasting at least 24 hours caused by inflammation or demyelination in the central nervous system.

"Compendia" are summaries of drug information and medical evidence to support decision-making about the appropriate use of drugs and medical procedures. Examples include, but are not limited to:

1. American Hospital Formulary Service Drug Information
2. Clinical pharmacology
3. National Comprehensive Cancer Network Drugs and Biologics Compendium
4. Thomson Micromedex DrugDex
5. United States Pharmacopeia-National Formulary (USP-NF)

"Disease-modifying therapy" is a medication that modifies the course of MS by reducing relapses and slowing disability progression.

"Documentation" refers to written information, including but not limited to:

- Up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses; or

- Prescription claims records, and/or prescription receipts to support prior trials of formulary alternatives.

"MRI" or "Magnetic Resonance Imaging" refers to a medical imaging technique that creates detailed three-dimensional (3D) images of the organs and tissues in your body. A brain MRI can reveal areas of active MS disease called lesions within the central nervous system.

"Multiple sclerosis" is a chronic autoimmune disease of the central nervous system characterized by inflammation, demyelination, and neurodegeneration.

"No evidence of" indicates that the reviewer has not identified any records of the specified item or condition within the submitted materials or claims history. In the absence of such evidence, the member is considered eligible. If any evidence of the item or condition is present upon review of the request, the member does not qualify.

"Primary progressive MS" refers to worsening neurologic function from the onset of symptoms, without early relapses or remissions.

"Relapse" is defined as the appearance of new symptoms or the worsening of existing symptoms lasting at least 24 hours in the absence of fever or infection.

"Relapsing-remitting MS" refers to a disease course characterized by clearly defined attacks of new or increasing neurologic symptoms followed by periods of partial or complete recovery.

"[s]" indicates state mandates may apply.

"Secondary progressive MS" is a disease course following relapsing-remitting MS that is characterized by a progressive worsening of neurologic function over time with or without relapses.

"Severe obstructive sleep apnea" is defined as an Apnea-hypopnea index (AHI) greater than 30 events per hour.

Clinical Indications

Medical Necessity Criteria for Clinical Review

General Medical Necessity Criteria

The Plan considers Zeposia (ozanimod) medically necessary when recent (within the last 3 months) clinical chart documentation provided indicates the member meets ONE of the following:

1. Authorization may be granted for pediatric members less than 18 years of age with multiple sclerosis when there is documentation that the benefits outweigh the risks; *OR*
Note: If approved, the requested product will be authorized for up until the member reaches 18 years of age.
2. The member meets ALL of the following:
 - a. The member meets ALL of the following:
 - No evidence of myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure in the last 6 months; *and*
 - No evidence of a presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the member has a functioning pacemaker; *and*
 - No evidence of severe untreated sleep apnea; *and*
 - b. No evidence of concomitant use of a monoamine oxidase (MAO) inhibitor; *AND*
 - c. Zeposia (ozanimod) is being prescribed at a dose and frequency that is within FDA approved labeling *OR* is supported by compendia or evidence-based published dosing guidelines for the requested indication. *The requested medication is being used within the Plan's Quantity Limit of; and*
 - *The recommended maintenance dose is 0.92 mg orally once daily.*
 1. *30 capsules per 30 days for maintenance dose (0.92 mg capsules).*
 - *Dosage must be titrated over 7 days according to the following schedule:*
 1. *Days 1-4: 0.23 mg once daily.*
 2. *Days 5-7: 0.46 mg once daily.*
 3. *Day 8 and thereafter: 0.92 mg once daily.*
 - d. The member meets the applicable [Medical Necessity Criteria for Initial Clinical Review](#) or [Subsequent Clinical Review](#) listed below.

Medical Necessity Criteria for Initial Clinical Review

Initial Indication-Specific Criteria

Multiple Sclerosis - Adults

The Plan considers Zeposia (ozanimod) medically necessary when recent (within the last 3 months) clinical chart documentation provided indicates the member meets ALL of the following:

3. The member meets the above applicable [General Medical Necessity Criteria](#); *AND*

4. Prescribed by or in consultation with a neurologist or physician who specializes in the treatment of multiple sclerosis; *AND*
5. The member is 18 years of age or older; *AND*
6. The member has ONE (1) of the following forms of multiple sclerosis:
 - a. Relapsing-remitting (RRMS); *or*
 - b. Active secondary progressive disease (SPMS); *or*
 - c. Clinically isolated syndrome (CIS).

If the above prior authorization criteria are met, the requested medication will be approved for up to 12-months.^[s]

Ulcerative Colitis

The Plan considers Zeposia (ozanimod) medically necessary when recent (within the last 3 months) clinical chart documentation provided indicates the member meets ALL of the following:

3. The member meets the above applicable [General Medical Necessity Criteria](#); *AND*
4. Prescribed by or in consultation with a gastroenterologist; *AND*
5. The member is 18 years of age or older; *AND*
6. Has a diagnosis of moderately to severely active ulcerative colitis.

If the above prior authorization criteria are met, the requested medication will be approved for up to 12-months.^[s]

Continued Care

[Medical Necessity Criteria for Subsequent Clinical Review](#)

Subsequent Indication-Specific Criteria

Multiple Sclerosis - Adults

The Plan considers Zeposia (ozanimod) medically necessary when recent (within the last 6-months) clinical chart documentation provided indicates the member meets ONE (1) of the following:

1. The member meets the above applicable [General Medical Necessity Criteria and Initial Indication-Specific Criteria](#); *AND*
2. The member meets ONE (1) of the following:
 - a. Improvement in at least ONE (1) objective measure, such as:
 - i. Reduced disease activity on MRI; *and/or*
 - ii. Improved or stable disability scores; *and/or*
 - iii. Reduced relapse rate; *and/or*
 - iv. Improved fatigue or walking assessments; *and/or*
 - b. The member has shown stabilization or improvement in at least ONE (1) MS symptom, such as:
 - i. Motor function; *and/or*

- ii. Fatigue; *and/or*
- iii. Vision; *and/or*
- iv. Bowel/bladder function; *and/or*
- v. Spasticity; *and/or*
- vi. Walking/gait; *and/or*
- vii. Pain/numbness/tingling.

If the above reauthorization criteria are met, the requested product will be authorized for up to 12-months.^[5]

Ulcerative Colitis

The Plan considers Zeposia (ozanimod) medically necessary when recent (within the last 6-months) clinical chart documentation provided indicates the member meets ONE (1) of the following:

1. The member meets the above applicable General Medical Necessity Criteria and Initial Indication-Specific Criteria; *AND*
2. The member meets ONE (1) of the following:
 - a. Improvement in at least ONE (1) objective measure, such as:
 - i. Reduced inflammatory markers (e.g., fecal calprotectin, C-reactive protein); *and/or*
 - ii. Improved appearance of mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE) or intestinal ultrasound;; *and/or*
 - iii. Improvement on a disease activity scoring tool (e.g., Ulcerative Colitis Endoscopic Index of Severity [UCEIS], Mayo Score); *and/or*
 - iv. Reduced corticosteroid dose; *or*
 - b. Improvement in at least ONE (1) symptom, such as:
 - i. Decreased pain; *and/or*
 - ii. Reduced fatigue; *and/or*
 - iii. Decreased stool frequency; *and/or*
 - iv. Reduced rectal bleeding; *and/or*
 - v. Reduced urgency of defecation.

If the above reauthorization criteria are met, the requested product will be authorized for up to 12-months.^[5]

Experimental or Investigational / Not Medically Necessary^[5]

Zeposia (ozanimod) for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary. Non-covered indications include, but are not limited to, the following:

- Use in combination with other disease-modifying therapies for MS or UC. The safety and efficacy of combining Zeposia with other DMTs or biologics have not been established.
- Treatment of mild UC or use as first-line therapy for UC before trial of conventional treatments. Current evidence and guidelines support its use in moderate to severe UC after failure of other therapies.
- Use for the treatment of non-relapsing forms of multiple sclerosis, such as primary progressive MS (PPMS). Treatment of other autoimmune or inflammatory conditions not specifically approved by the FDA. While Zeposia's mechanism of action may suggest potential benefits in other conditions, clinical evidence is currently insufficient to support its use outside of approved indications.
- Use individuals under the age of 18 for UC. The safety and efficacy in pediatric populations has not been established for this indication.
- Treatment of Alzheimer's disease. There are no studies to support the use of Zeposia (ozanimod) for the management of Alzheimer's disease.

References

1. Bainbridge JL, Miravalle A, Wong PS. Multiple Sclerosis. In DiPiro JT, Yee GC, Posey LM, et al, eds. *Pharmacotherapy: A Pathophysiologic Approach*. 11th ed. New York, NY: McGraw-Hill; 2019.
2. Benallegue N, Rollot F, Wiertlewski S, Casey R, Debouverie M, Kerbrat A, De Seze J, Ciron J, Ruet A, Labauge P, Maillart E, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Heinzlef O, Pelletier J, Thouvenot E, Al Khedr A, Bourre B, Casez O, Cabre P, Wahab A, Magy L, Vukusic S, Laplaud DA; OFSEP (Observatoire Français de la Sclérose en Plaques) Investigators. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis. *JAMA Neurol*. 2024 Mar 1;81(3):273-282.
3. Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, Yeh EA, Bykova O, Wassmer E, Tardieu M, Kornberg A, Ghezzi A; International Pediatric Multiple Sclerosis Study Group. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. *Mult Scler*. 2012 Jan;18(1):116-27.
4. Cohen JA, Arnold DL, DeLuca J, et al. Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials. *Mult Scler*. 2025 Sep;31(10):1218-1230. doi: 10.1177/13524585251355842. Epub 2025 Jul 23.
5. Cohen JA, Comi G, Selmaj KW, et al,. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. *Lancet Neurol*. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.
6. Comi G, Kappos L, Selmaj KW, et al,. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. *Lancet Neurol*. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3.
7. Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. *J Clin Med*. 2022 Apr 20;11(9):2302. doi: 10.3390/jcm11092302.
8. Feuerstein JD, Isaacs KL, Schneider Y et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. *Gastroenterology*. 2020; 158:1450-1461. [PubMed 31945371].
9. Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. *Am J Med*. 2020 Dec;133(12):1380-1390.e2. doi: 10.1016/j.amjmed.2020.05.049. Epub 2020 Jul 17

10. He A, Merkel B, Brown JW, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. *Lancet Neurol.* 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18.
11. Köhler M, Paul F, Janke K, et al. Comparative effectiveness of disease-modifying therapies for highly active relapsing-remitting multiple sclerosis despite previous treatment - a systematic review and network meta-analysis. *BMC Neurol.* 2025 Aug 9;25(1):328. doi: 10.1186/s12883-025-04338-7.
12. Krysko KM, Graves JS, Rensel M, et al; US Network of Pediatric MS Centers. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. *Ann Neurol.* 2020 Jul;88(1):42-55.
13. Krysko KM, Graves J, Rensel M, et al; US Network of Pediatric MS Centers. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. *Neurology.* 2018 Nov 6;91(19):e1778-e1787.
14. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. *JAMA.* 2021;325(8):765-779. doi:10.1001/jama.2020.26858
15. Montalban X, Gold R, Thompson AJ, et al.ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. *Eur J Neurol.* 2018;25(2):215-237. doi:10.1111/ene.13536
16. Montalban X, Lebrun-Frény C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. *Lancet Neurol.* 2025 Oct;24(10):850-865. doi: 10.1016/S1474-4422(25)00270-4. Erratum in: *Lancet Neurol.* 2025 Nov;24(11):e13. doi: 10.1016/S1474-4422(25)00355-2.
17. Multiple Sclerosis Society of Canada. Disease-modifying therapies. <https://mssociety.ca/managing-ms/treatments/medications/disease-modifying-therapies-dmts>.
18. National Institute for Health and Care Excellence [NICE]. Multiple sclerosis in adults: management. NICE Guidelines [NG220]. 22 June 2022. Available at: <https://www.nice.org.uk/guidance/ng220/chapter/Recommendations#ms-symptom-management-and-rehabilitation>. Accessed 20 January 2026.
19. National MS Society. Disease-modifying therapies for MS (updated March 2022). Available from National MS Society website: <https://nms2cdn.azureedge.net/cmssite/nationalmssociety/media/msnationalfiles/brochures/brochure-the-ms-disease-modifying-medications.pdf>.
20. Paik J. Ozanimod: A Review in Ulcerative Colitis. *Drugs.* 2022 Aug;82(12):1303-1313. doi: 10.1007/s40265-022-01762-8. Epub 2022 Aug 22. Erratum in: *Drugs.* 2022 Aug;82(12):1315. doi: 10.1007/s40265-022-01772-6.
21. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology.* 2018;90(17):777-788.
22. Raine T, Bonovas S, Burisch J, et al,. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. *J Crohns Colitis.* 2022 Jan 28;16(1):2-17. doi: 10.1093/ecco-jcc/jjab178. PMID: 34635919.
23. Rashid W, Ciccarelli O, Leary SM, et al. Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance. *Pract Neurol.* 2025 Jan 16;25(1):18-24. doi: 10.1136/pn-2024-004228.
24. Reich DS, Lucchinetti CF, Calabresi PA. 2018. Multiple sclerosis. *New England Journal of Medicine* 378(2):169-180
25. Rubin DT, Ananthakrishnan AN, Siegel CA et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol.* 2019; 114:384-413. [PubMed 30840605].
26. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. *Am J Gastroenterol.* 2025 Jun 3;120(6):1187-1224. doi: 10.14309/ajg.0000000000003463.

27. Sandborn WJ, Feagan BG, D'Haens G, et al,. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med*. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
28. Sands BE, Rubin DT, Loftus EV Jr, et al. Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial. *Am J Gastroenterol*. 2025 Oct 1;120(10):2339-2349. doi: 10.14309/ajg.0000000000003310. Epub 2025 Jan 8.
29. Selmaj KW, Steinman L, Comi G, et al. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial. *Mult Scler*. 2025 Nov;31(13):1557-1571. doi: 10.1177/13524585251382796. Epub 2025 Nov 5.
30. Singh S, Loftus EV Jr, Limketkai BN, et al,. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. *Gastroenterology*. 2024 Dec;167(7):1307-1343. doi: 10.1053/j.gastro.2024.10.001.
31. Sladowska K, Mocko P, Brzostek T, et al. Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies. *Mult Scler Relat Disord*. 2025. doi: 10.1016/j.msard.2025.106263
32. Sriwastava S, Chaudhary D, Srivastava S, et al. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature. *J Neurol*. 2022;269(3):1678-1687. doi:10.1007/s00415-021-10910-1
33. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence summary. Multiple Sclerosis Coalition. Available from the National MS Society Website: <https://www.nationalmssociety.org/>.
34. Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. *Cochrane Database Syst Rev* 2015;9:CD011381.
35. Ulcerative colitis: management. London: National Institute for Health and Care Excellence (NICE); 2019 May 3.
36. Walsh R, Chitnis T. Therapeutic Advances in Pediatric Multiple Sclerosis. *Children*. 2025;12(3):259.
37. Yang, J., Rempe, T., Whitmire, N., Dunn-Pirio, A., & Graves, J. (2022). Therapeutic Advances in Multiple Sclerosis. *Frontiers in Neurology*, 13. <https://doi.org/10.3389/fneur.2022.824926>.
38. Yarur A, Irving P, Siegmund B, et al. Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid. *Inflamm Bowel Dis*. 2026 Jan 1;32(1):77-86. doi: 10.1093/ibd/izaf195.
39. Zeposia (ozanimod) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; August 2024.

Clinical Guideline Revision / History Information

Original Date: 06/27/2024

Reviewed/Revised: 8/29/2024, 10/01/2025, 04/01/2026, 05/01/2026